Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Recruiting 2Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 3Expanded_access 1

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 2Lymphoid 2

Conditions

Breast Neoplasms 543Neoplasms 449Carcinoma, Non-Small-Cell Lung 410Prostatic Neoplasms 334Colorectal Neoplasms 315Lung Neoplasms 261Multiple Myeloma 229Neoplasm Metastasis 190Pancreatic Neoplasms 186Leukemia, Myeloid, Acute 183Ovarian Neoplasms 178Melanoma 147Squamous Cell Carcinoma of Head and Neck 140Carcinoma, Hepatocellular 116Recurrence 115Head and Neck Neoplasms 114Carcinoma, Renal Cell 112Lymphoma 111Stomach Neoplasms 110Endometrial Neoplasms 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Glioblastoma 108Brain Neoplasms 106Lymphoma, Non-Hodgkin 105Uterine Cervical Neoplasms 100Triple Negative Breast Neoplasms 97Urinary Bladder Neoplasms 95Hematologic Neoplasms 91Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Large B-Cell, Diffuse 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × 30 days × Clear all
NCT06915766 2026-05-28

Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

Cogent Biosciences, Inc.

Available
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT04910685 2026-05-22

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Blueprint Medicines Corporation

Phase 2/3 Recruiting
534 enrolled
Myeloid

Mastocytosis, Systemic

NCT05186753 2026-05-22

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Cogent Biosciences, Inc.

Phase 2 Active not recruiting
237 enrolled
Myeloid

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Mastocytosis, Mastocytosis, Systemic

NCT05362773 2026-05-22

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

MacroGenics

Phase 1 Recruiting
130 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Hairy Cell, Myelodysplastic Syndromes, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡